Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data

Agelink, M.W.; Ullrich, Hermann; Baumann, B.; Strum, Sima; Majewski, T.

doi:10.1007/s00213-002-1146-7

Cited by 27 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Duplicates were removed, titles and abstracts scanned, potential articles read and evaluated against inclusion criteria and authors contacted for additional data when necessary. In total, 140 case-control and 30 treatment 76,83,93,110,116,129,138,141,155,175,[187][188][189][190][191][192][193][194][195][196][197][198][199][200][201][202][203][204][205][206] studies were eligible for inclusion in the quantitative synthesis (151 case-control and 43 effect sizes for analysis); 10 of the studies were included in both the case-control and treatment analyses. 76,83,93,110,116,129,138,141,155,175 Four subgroups of disorders (mood, anxiety-related, psychotic and substance dependence disorders) and 2 classes of psychotropic medications (antidepressants and antipsychotics) were included.…”

Section: Description Of Included Studiesmentioning

confidence: 99%

Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis

Alvares

Quintana

Hickie

et al. 2016

jpn

378

345

View full text Add to dashboard Cite

Section: Description Of Included Studiesmentioning

confidence: 99%

Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis

Alvares

Quintana

Hickie

et al. 2016

jpn

378

345

View full text Add to dashboard Cite

“…Only a handful of investigations have examined pretreatment HRV as a predictor of antidepressant outcomes in MDD. Early studies ( N ≤ 25) did not find any significant associations between baseline autonomic characteristics and antidepressant outcomes (Agelink et al., ; Agelink, Ullrich, Baumann, Strum, & Majewski, ).…”

Section: Introductionmentioning

confidence: 98%

Heart rate variability as a biomarker of anxious depression response to antidepressant medication

2018

View full text Add to dashboard Cite

Background: There is a need to identify biomarkers of treatment outcomes for Major Depressive Disorder (MDD) that can be disseminated. We investigated the predictive utility of pre-treatment heart rate variability (HRV) for outcomes of antidepressant medication in MDD, with pre-treatment anxious depression as a hypothesized moderator of HRV effects. Methods: A large, randomized, multicenter practical trial (International Study to Predict Optimized Treatment-in Depression; iSPOT-D) in patients with current nonpsychotic MDD (N=1,008; 722 completers) had three arms: escitalopram, sertraline, and venlafaxine-extended release. At pre-treatment, patients were defined as having anxious (N=309) versus nonanxious (N=413) depression and their resting high-frequency HRV (root mean square of successive differences; RMSSD) was assessed. Patients’ usual treating clinicians managed medication. At 8 weeks, primary outcomes were clinician-rated depressive symptom response and remission; secondary outcomes were self-reported response and remission. Results: Pre-treatment HRV predicted antidepressant outcomes as a function of anxious versus nonanxious depression. In anxious depression, patients with higher HRV had better outcomes, whereas patients with lower HRV had poorer outcomes. In nonanxious depression, patients with lower HRV had better outcomes, whereas patients with higher HRV had poorer outcomes. Some simple effects were not significant. Results did not differ by treatment arm and remained significant when controlling for important covariates. Conclusions: These findings inform a precision medicine approach in which clinical and biological assessments may be integrated to facilitate treatment outcome prediction. Knowing about HRV may help determine which patients with anxious depression could benefit from antidepressants and which patients may require a different treatment approach. Trial Registration: International Study to Predict Optimized Treatment-in Depression; NCT00693849; https://clinicaltrials.gov/ct2/show/NCT00693849

show abstract

“…That is, unlike increases in heart rate (HR), which could be due to either increased SNS activity or decreased PNS activity or some combination, decreases in HRV are thought to reflect the unique contribution of the SNS. Lower HRV is associated with a number of markers of SNS activation, such as muscle sympathetic nerve activity (Kingwell et al, 1994), norephinephrine activity (Agelink, Ullrich, Baumann, Strum, & Majewski, 2002), and perceived stress (Vrijkotte, van Doornen, & de Geus, 2000). In addition to directly measuring the effects of SNS (and PNS) activation, HRV has the advantage of being a continuous measure, which allows one to observe effects across the full range of data rather than discrete high-medium-low groupings, as has been the case in prior studies of this nature.…”

mentioning

confidence: 99%

Evidence for a curvilinear relationship between sympathetic nervous system activation and women's physiological sexual arousal

et al. 2011

View full text Add to dashboard Cite

There is increasing evidence that women’s physiological sexual arousal is facilitated by moderate sympathetic nervous system (SNS) activation. Literature also suggests that the level of SNS activation may play a role in the degree to which SNS activity affects sexual arousal. We provide the first empirical examination of a possible curvilinear relationship between SNS activity and women’s genital arousal using a direct measure of SNS activation in 52 sexually functional women. The relationship between heart rate variability (HRV), a specific and sensitive marker of SNS activation, and vaginal pulse amplitude (VPA), a measure of genital arousal, was analyzed. Moderate increases in SNS activity were associated with higher genital arousal, while very low or very high SNS activation was associated with lower genital arousal. These findings imply that there is an optimal level of SNS activation for women’s physiological sexual arousal.

show abstract

Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data

Cited by 27 publications

References 24 publications

Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis

Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis

Heart rate variability as a biomarker of anxious depression response to antidepressant medication

Evidence for a curvilinear relationship between sympathetic nervous system activation and women's physiological sexual arousal

Contact Info

Product

Resources

About